Prostate cancer-expressed EZH2-associated transcript (PCSEAT)

Prostate cancer-expressed EZH2-associated transcript (PCSEAT), also known as PRCAT38, is a long non-coding RNA highly expressed in prostate cancer tissue. It exhibits oncogenic properties and functions as a competing endogenous RNA that associates with EZH2, a key histone methyltransferase involved in gene silencing and prostate cancer biology. PCSEAT/PRCAT38 is believed to participate in regulatory networks influencing cancer progression, but is not itself a protein, enzyme, or receptor and is not currently a direct drug target. It represents a class of cancer-associated lncRNAs that may regulate gene expression through interactions with chromatin modifiers such as EZH2. PRCAT38 is identified as the gene symbol LOC117134611 in some databases, and while associated with prostate cancer, it is a non-coding RNA distinct from protein targets. Most current research interest is in its role as a gene expression regulator, not as a direct therapeutic target or established biomarker. There are no approved drugs, mechanisms of action, or specific safety concerns associated with direct targeting of PCSEAT/PRCAT38, reflecting its classification as a regulatory RNA, not a biological receptor or enzyme.

Other names

PRCAT38Prostate cancer-associated transcript 38PCa specific expression and EZH2-associated transcriptPCSEAT